Lilly Reports Results of Taltz (ixekizumab) in P-III COAST-V and COAST-W trials for Ankylosing Spondylitis (AS)

 Lilly Reports Results of Taltz (ixekizumab) in P-III COAST-V and COAST-W trials for Ankylosing Spondylitis (AS)

Shots:

  • The two P-III trials i.e. COAST-V (N=341) & COAST-W (N=316) involves assessing of Taltz (80/160 mg, q4w/q2w) SC vs adalimumab, or PBO in patients with AS never undergone bDMARD drug and intolerant to TNF inhibitors respectively
  • COAST-V and COAST-W Results: @16 wks.: ASAS40 (48%, 25%; 52% ,31% vs 18%, 13%); ASAS20 (64%, 48%; 69%, 47% vs 40%, 25%); BASDAI50 (42%, 43% vs 17%): (-2.2 ± 0.2, -2.1 ± 0.2 & -0.9 ± 0.2); MRI Spine SPARCC CFB: (-11.0, -11.0; -9.6, -9.6 vs -1.5, -1.5)
  • Taltz is a mAb binds with interleukin 17A (IL-17A), and is approved treatment for PA & moderate-to-severe plaque psoriasis in adults. Lilly plans to file BLA under the US FDA with reference to above results in AS/radiographic axSpA

Click here to read full press release/ article | Ref: Eli Lilly | Image: Bolon

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post